Texas Capital Bancshares: Still Not Good Enough for an Upgrade
Finance

Texas Capital Bancshares: Still Not Good Enough for an Upgrade

authorBy Suze Orman
DateJun 25, 2026
Read time2 min

Texas Capital Bancshares (TCBI) continues to receive a 'Hold' recommendation, primarily due to ongoing concerns regarding its market valuation, a substantial portion of uninsured deposits, and what is deemed only satisfactory asset quality. The bank's expansion in deposits is largely fueled by brokered deposits, which are typically more expensive, rather than robust organic growth. A significant 41% of its deposits remain uninsured. Although the net interest margin has seen an increase to 3.43% and non-interest income has risen, key profitability indicators such as Return on Assets (0.95%) and Return on Equity (8.35%) are still below optimal thresholds. Currently, TCBI's price-to-earnings ratio stands at 15.9, surpassing both its industry peers and the author's preferred limit, even though its price-to-book ratios are considered reasonable.

Last September, an in-depth analysis of Texas Capital Bancshares was conducted to assess its potential for an upgrade. Despite the desire to elevate its rating, several factors prevented this. The prevailing market valuation, coupled with the concerns outlined above, suggested that an upgrade was premature. The bank's reliance on brokered deposits highlights a potential vulnerability, as these deposits are often less stable and more sensitive to interest rate changes. This deposit structure, combined with a high percentage of uninsured deposits, poses a risk to the bank's financial stability, particularly in volatile economic conditions. The modest organic deposit growth further underscores the challenge in attracting and retaining traditional, lower-cost deposits.

Furthermore, while the expansion of the net interest margin and the increase in non-interest income are positive developments, they have not translated into a significant improvement in overall profitability as measured by ROA and ROE. These metrics are crucial indicators of how efficiently a bank is generating earnings from its assets and equity. The fact that they lag behind preferred benchmarks suggests that TCBI may not be fully optimizing its operational efficiency or capital deployment. The elevated price-to-earnings ratio implies that the market is assigning a higher value to TCBI compared to its peers, which could be unsustainable given the existing concerns. This suggests that the stock might be overvalued relative to its fundamental performance and risk profile.

In conclusion, Texas Capital Bancshares remains in a holding pattern. While the bank has shown some improvements in certain areas, the persistent issues related to valuation, deposit composition, and profitability metrics continue to temper enthusiasm for an upgrade. Investors should carefully consider these factors and monitor the bank's progress in addressing these challenges before making any significant investment decisions.

More Articles
Finance
FitLife Brands: Irwin Naturals Acquisition Bolsters Revenue Growth
FitLife Brands' strategic acquisition of Irwin Naturals in August 2025 has significantly diversified its product offerings and distribution channels, leading to a substantial 59% year-over-year revenue increase in Q1 2026. This acquisition has successfully offset weaknesses in the legacy business, showcasing the strength of FTLF's acquisition-led growth strategy. Irwin Naturals' strong performance on Amazon, generating $9-10 million in annual revenue, highlights its long-term potential for FTLF's top line.
By Robert KiyosakiJun 25, 2026
Finance
Identifying Secure Dividend Investment Prospects from Barron's 'Better Bets'
Even with persistent long-term bond yields, investors seeking steady income can find compelling opportunities in dividend-paying stocks. Barron's highlights that specific high-yield stocks can still offer superior returns compared to traditional Treasury bills. The article emphasizes that truly secure dividend investments come from companies with positive free cash flow and a history of sustained dividend growth, filtering out many lower-rated options.
By Fareed ZakariaJun 25, 2026
Finance
Spotify: A Renewed Opportunity for Investors?
This article explores the recent positive developments that have improved Spotify's market outlook. Previously, a neutral stance on the stock proved cautious as it declined by 21% over six months. However, new information suggests a reassessment of Spotify's investment potential, indicating a possible shift towards new opportunities for investors.
By Robert KiyosakiJun 25, 2026
Finance
Alumis: Upcoming Data Catalysts for Envudeucitinib
Alumis has received a renewed 'Buy' rating due to anticipated data releases for its primary drug candidate, envudeucitinib, targeting psoriasis and SLE. While initial Phase 3 trials showed promising efficacy and safety, the drug's twice-daily dosing regimen presents a slight drawback. Key catalysts for 2026 include long-term psoriasis data, NDA submission, and pivotal SLE data, all crucial for the company's valuation and potential acquisition. Given competitive pressures and a limited pipeline, ALMS remains a high-risk, catalyst-driven investment, though current cash reserves offer near-term stability.
By Robert KiyosakiJun 25, 2026
Finance
Weekly Dividend Growth Update: Notable Increases from HEI and WKC
This article provides a weekly summary of dividend announcements from over 700 dividend growth stocks. This past week saw only two companies in the author's database, HEI and WKC, declare dividend increases. HEI announced its 18th consecutive annual dividend increase, while WKC significantly boosted its quarterly payout. The analysis highlights their differing profiles, with HEI being a growth compounder and WKC's dividend safety being less robust.
By Nouriel RoubiniJun 25, 2026